强骨生血口服液联合骨化三醇治疗绝经后骨质疏松的临床研究  

Clinical study on Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis

作　　者：陈艳[1] 余祖光[1] CHEN Yan;YU Zuguang(Wuhan Hospital of Traditional Chinese Medicine,Wuhan 430000,China)

机构地区：[1]武汉市中医医院,湖北武汉430000

出　　处：《现代药物与临床》2024年第1期205-208,共4页Drugs & Clinic

基　　金：湖北省卫生健康委员会科研项目(WJ2019F163)。

摘　　要：目的 探讨强骨生血口服液联合骨化三醇治疗妇女绝经后骨质疏松的临床疗效。方法 选取2022年6月—2023年6月在武汉市中医院诊治的124例绝经后骨质疏松患者,随机分为对照组(62例)和治疗组(62例)。对照组患者口服骨化三醇胶丸,0.25μg/次,2次/d。在对照组的基础上,治疗组口服强骨生血口服液,30 mL/次,3次/d。两组患者连服12周。观察两组患者临床疗效,比较治疗前后两组患者症状好转时间,骨代谢指标骨钙蛋白(BGP)、骨碱性磷酸酶(BALP)、骨保护素(OPG)和N-端骨钙素(N-MID)水平及血清胰岛素样生长因子-1(ICF-1)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平。结果 治疗后,治疗组临床总有效率为98.39%,明显高于对照组(83.87%,P<0.05)。治疗后,治疗组症状好转时间均明显短于低于对照组(P<0.05)。治疗后,两组患者BGP、BALP、OPG和ICF-1水平明显升高,而N-MID、IL-6、TNF-α、CRP水平明显降低(P<0.05),且治疗组这些指标水平明显好于对照组(P<0.05)。结论 强骨生血口服液联合骨化三醇治疗效果确切,能显著缓解临床症状,有效提高骨代谢能力,并促进机体炎症反应减弱。Objective To investigate the clinical efficacy of Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis.Methods Patients(124 cases)with postmenopausal osteoporosis in Wuhan Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were randomly divided into control(62 cases)and treatment(62 cases)group.Patients in the control group were po administered with Calcitriol Soft Capsules,0.25μg/time,twice daily.Patients in the treatment group were po administered with Qianggu Shengxue Oral Liquid on the basis of the control group,30 mL/time,three times daily.Patients in two groups were treated for 12 weeks.After treatment,the clinical evaluations was evaluated,the time of symptom relief,the levels of bone metabolic markers BGP,BALP,OPG and N-MID,the serological IL-6,TNF-α,CRP and ICF-1 levels in two groups before and after treatment were compared.Results After treatment,the clinical effective rate in the treatment group was 98.39%,which was significantly higher than that of the control group(83.87%,P<0.05).After treatment,the time of symptom improvement in the treatment group was significantly shorter than that in the control group(P<0.05).After treatment,the levels of BGP,BALP,OPG and ICF-1 were significantly increased,while the levels of N-MID,IL-6,TNF-αand CRP were significantly decreased in two groups,and these indexes in the treatment group were significantly better than those in the control group(P<0.05).Conclusion Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis has a definite therapeutic effect,which can significantly relieve clinical symptoms,effectively improve bone metabolism,and promote the weakening of inflammatory reaction.

关 键 词：强骨生血口服液 骨化三醇胶丸 妇女绝经后骨质疏松 骨钙蛋白 骨碱性磷酸酶 N-端骨钙素 胰岛素样生长因子-1 

分 类 号：R982[医药卫生—药品]